₩180,000.00
1.10% day before yesterday
Korea, Dec 26, 07:30 am CET
ISIN
KR7068270008
Symbol
068270
Index

Celltrion Stock price

₩180,000.00
-7,400.00 3.95% 1M
+19,800.00 12.36% 6M
-288.47 0.16% YTD
+5,383.70 3.08% 1Y
+26,887.10 17.56% 3Y
-98,629.80 35.40% 5Y
+125,761.10 231.87% 10Y
+175,313.11 3,740.50% 20Y
Korea, Closing price Fri, Dec 26 2025
-2,000.00 1.10%
ISIN
KR7068270008
Symbol
068270
Index
Industry

Key metrics

Basic
Market capitalization
₩41.6t
Enterprise Value
₩43.5t
Net debt
₩2.0t
Cash
₩918.3b
Shares outstanding
218.8m
Valuation (TTM | estimate)
P/E
53.5 | 48.1
P/S
10.7 | 9.9
EV/Sales
11.2 | 10.3
EV/FCF
88.2
P/B
2.5
Dividends
DPS
₩750.00
Yield 1Y | 5Y
0.4% | 0.3%
Growth 1Y | 5Y
4.0% | -
Payout 1Y | 3Y
38.1% | 21.5%
Increased
3 Years
Financials (TTM | estimate)
Revenue
₩3.9t | ₩4.2t
EBITDA
₩960.3b | ₩1.5t
EBIT
₩889.7b | ₩1.2t
Net Income
₩737.8b | ₩819.0b
Free Cash Flow
₩493.9b
Growth (TTM | estimate)
Revenue
35.5% | 18.3%
EBITDA
101.3% | 123.0%
EBIT
183.3% | 134.7%
Net Income
294.4% | 93.8%
Free Cash Flow
18.1%
Margin (TTM | estimate)
Gross
55.4%
EBITDA
24.7% | 35.7%
EBIT
22.8%
Net
18.9% | 19.5%
Free Cash Flow
12.7%
Financial Health
Equity Ratio
82.8%
Return on Equity
2.4%
ROCE
5.2%
ROIC
3.9%
Debt/Equity
0.2
More
EPS
₩3,363.6
FCF per Share
₩2,257.6
Short interest
-
Employees
-
Rev per Employee
-
Show more

Is Celltrion a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Celltrion Stock Analysis

Unlock Scores for Free

Analyst Opinions

29 Analysts have issued a Celltrion forecast:

24x Buy
83%
4x Hold
14%
1x Sell
3%

Analyst Opinions

29 Analysts have issued a Celltrion forecast:

Buy
83%
Hold
14%
Sell
3%

Financial data from Celltrion

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
3,895,987 3,895,987
35% 35%
100%
- Direct Costs 1,738,855 1,738,855
9% 9%
45%
2,157,131 2,157,131
69% 69%
55%
- Selling and Administrative Expenses 977,875 977,875
59% 59%
25%
- Research and Development Expense 218,935 218,935
16% 16%
6%
960,322 960,322
101% 101%
25%
- Depreciation and Amortization 70,618 70,618
57% 57%
2%
EBIT (Operating Income) EBIT 889,704 889,704
183% 183%
23%
Net Profit 737,835 737,835
294% 294%
19%

In millions KRW.

Don't miss a Thing! We will send you all news about Celltrion directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Celltrion, Inc. engages in the development, manufacture and distribution of pharmaceuticals. It operates through the Biopharmaceuticals, Chemical Drugs and Others businesses. Its products include remsima and biosimilars. The company was founded on February 27, 1991 and is headquartered in Incheon, South Korea.

Head office South Korea
CEO Wu-Sung Ki
Founded 1991
Website www.celltrion.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today